BIIB Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of 16.99%. Biogen, Inc.'s return on equity of 7.36% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Biogen, Inc. has a consensus price target of $205.52, signalling upside risk potential of 4.58%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $459.40 which suggests that it could grow by 48.74%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.160, which suggesting that the stock is 84.033% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.2B, which are larger than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Biogen, Inc.'s net income of -$48.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Biogen, Inc.'s price-to-earnings ratio is 22.32x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 3.03x versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of 34.4%. Biogen, Inc.'s return on equity of 7.36% beat Eli Lilly & Co.'s return on equity of 104.39%.

Biogen, Inc. has a consensus price target of $205.52, signalling upside risk potential of 4.58%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 15.54%. Given that Eli Lilly & Co. has higher upside potential than Biogen, Inc., analysts believe Eli Lilly & Co. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.160, which suggesting that the stock is 84.033% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.73 per share. Biogen, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.2B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Biogen, Inc.'s net income of -$48.9M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Biogen, Inc.'s price-to-earnings ratio is 22.32x while Eli Lilly & Co.'s PE ratio is 46.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 3.03x versus 14.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of 18.06%. Biogen, Inc.'s return on equity of 7.36% beat Merck & Co., Inc.'s return on equity of 39.63%.

Biogen, Inc. has a consensus price target of $205.52, signalling upside risk potential of 4.58%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.86%. Given that Biogen, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Biogen, Inc. is more attractive than Merck & Co., Inc..

Biogen, Inc. has a beta of 0.160, which suggesting that the stock is 84.033% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. Biogen, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen, Inc. quarterly revenues are $2.2B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Biogen, Inc.'s net income of -$48.9M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Biogen, Inc.'s price-to-earnings ratio is 22.32x while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 3.03x versus 4.68x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of -2.24% compared to Biogen, Inc.'s net margin of -360.68%. Biogen, Inc.'s return on equity of 7.36% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Biogen, Inc. has a consensus price target of $205.52, signalling upside risk potential of 4.58%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $41.89 which suggests that it could grow by 31.27%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..

Biogen, Inc. has a beta of 0.160, which suggesting that the stock is 84.033% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.101, suggesting its more volatile than the S&P 500 by 10.054%.

Biogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Biogen, Inc. quarterly revenues are $2.2B, which are larger than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Biogen, Inc.'s net income of -$48.9M is lower than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Biogen, Inc.'s price-to-earnings ratio is 22.32x while Stoke Therapeutics, Inc.'s PE ratio is 48.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen, Inc. is 3.03x versus 9.05x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.